Echo Therapeutics (ECTE) Underwriters Exercise Full Overallotment in 3.2M Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Echo Therapeutics (ECTE) Closes 3.2M Offering at 95c/Share
December 27, 2012 4:16 PM ESTEcho Therapeutics, Inc. (Nasdaq: ECTE) announced the closing of a previously announced underwritten public offering of 3,200,000 shares of its common stock and the fully exercised over-allotment option to purchase 480,000 additional shares, offered at a price of $0.95 per share. The gross proceeds to Echo from this offering... More
Echo Therapeutics (ECTE) Prices 3.2M Offering at 95c/Share
December 21, 2012 7:06 AM ESTEcho Therapeutics, Inc. (Nasdaq: ECTE) today announced the pricing of a previously announced underwritten public offering of 3,200,000 shares of its common stock, offered at a price to the public of $0.95 per share. The gross proceeds to Echo from this offering are expected to be approximately $3.0... More
Echo Therapeutics (ECTE) Announces Common Offering
December 20, 2012 4:26 PM ESTEcho Therapeutics, Inc. (Nasdaq: ECTE) intends to offer for sale its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be... More
